RUBIUS THERAPEUTICS INC (RUBY) Stock Price, Quote, News and Overview
NASDAQ:RUBY - Nasdaq - US78116T1034 - Common Stock - Currency: USD
RUBY Quote, Performance and Key Statistics
0.083
-0.04 (-33.55%)
The current stock price of RUBY is 0.083 USD. In the past month the price decreased by -70.19%. In the past year, price decreased by -98.34%.
RUBY Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About RUBY
Company Profile
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company is headquartered in Foxboro, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2018-07-18. The firm is engaged in developing medicines called Red Cell Therapeutics (RCTs). Its RED PLATFORM is designed to genetically engineer, and culture Red Cell Therapeutics that are ready-to-use cellular therapies for the treatment of cancer and autoimmune diseases. The company develops RCT product candidates based on therapeutic modalities such as immune system stimulation for the treatment of cancer and immune modulation to induce tolerance in autoimmune diseases. Its oncology program, RTX-240, is in the Phase I/II clinical trial for relapsed/refractory or solid tumors and in the Phase I clinical trial for relapsed/refractory acute myeloid leukemia (AML). Its RTX-321 is an allogeneic artificial antigen presenting cell (aAPC) product candidate, which is in the Phase I clinical trial for the treatment of advanced human papillomavirus (HPV) 16-positive cancers.
Company Info
RUBIUS THERAPEUTICS INC
C/O Verdolino & Lowey, P.C., 124 Washington Street, Suite 101
FOXBORO MASSACHUSETTS 02139 US
CEO: Pablo J. Cagnoni
Employees: 9
Company Website: https://www.rubiustx.com/
Phone: 16176799600.0
RUBIUS THERAPEUTICS INC / RUBY FAQ
What is the stock price of RUBIUS THERAPEUTICS INC today?
The current stock price of RUBY is 0.083 USD. The price decreased by -33.55% in the last trading session.
What is the ticker symbol for RUBIUS THERAPEUTICS INC stock?
The exchange symbol of RUBIUS THERAPEUTICS INC is RUBY and it is listed on the Nasdaq exchange.
On which exchange is RUBY stock listed?
RUBY stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for RUBIUS THERAPEUTICS INC stock?
7 analysts have analysed RUBY and the average price target is 1.02 USD. This implies a price increase of 1128.92% is expected in the next year compared to the current price of 0.083. Check the RUBIUS THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RUBIUS THERAPEUTICS INC worth?
RUBIUS THERAPEUTICS INC (RUBY) has a market capitalization of 7.50M USD. This makes RUBY a Nano Cap stock.
How many employees does RUBIUS THERAPEUTICS INC have?
RUBIUS THERAPEUTICS INC (RUBY) currently has 9 employees.
What are the support and resistance levels for RUBIUS THERAPEUTICS INC (RUBY) stock?
RUBIUS THERAPEUTICS INC (RUBY) has a resistance level at 0.16. Check the full technical report for a detailed analysis of RUBY support and resistance levels.
Should I buy RUBIUS THERAPEUTICS INC (RUBY) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RUBY, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RUBY, evaluating the profitability, health, valuation and growth aspects
- RUBIUS THERAPEUTICS INC (RUBY) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RUBIUS THERAPEUTICS INC (RUBY) Sales and EPS estimates to see what analysts future expectations are.
- RUBIUS THERAPEUTICS INC (RUBY) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RUBIUS THERAPEUTICS INC (RUBY) Insider and Institutional Ownership to learn about the owners and their transactions.
- RUBIUS THERAPEUTICS INC (RUBY) Stock Chart to make your own analysis
- RUBIUS THERAPEUTICS INC (RUBY) Latest news and press-releases to stay up to date.
Does RUBIUS THERAPEUTICS INC (RUBY) stock pay dividends?
RUBY does not pay a dividend.
When does RUBIUS THERAPEUTICS INC (RUBY) report earnings?
RUBIUS THERAPEUTICS INC (RUBY) will report earnings on 2023-05-08.
What is the Price/Earnings (PE) ratio of RUBIUS THERAPEUTICS INC (RUBY)?
RUBIUS THERAPEUTICS INC (RUBY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.99).
RUBY Technical Analysis
RUBY Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RUBY. Both the profitability and financial health of RUBY have multiple concerns.
RUBY Financial Highlights
Over the last trailing twelve months RUBY reported a non-GAAP Earnings per Share(EPS) of -1.99. The EPS increased by 10.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RUBY Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to RUBY. The Buy consensus is the average rating of analysts ratings from 7 analysts.